In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genetic MicroSystems Inc.

Division of Thermo Fisher Scientific Inc.

Latest From Genetic MicroSystems Inc.

Motorola: Paging Diagnostics

Motorola is developing an expertise in microarray manufacturing to use as the jump-off point for a new life sciences initiative it hopes will turn into a high-margin, high-growth diagnostics business. It has spent $500 million in external investments to support the venture, including the $280 million acquisition of a clinical diagnostics start-up. But with its investors concerned with the recent downturn in demand in its core high-tech manufacturing businesses, the company is understandably reticent about touting the possibility of life sciences being its next big thing. On the other hand, should Motorola gain momentum and demonstrate an ability to tap the clinical diagnostics markets, the biochip initiative could ultimately become a broad-based point-of-care play, with the company drawing on its expertise in wireless communications to produce interactive handheld devices that would capture and transmit data to a remote site for analysis.
Medical Device Strategy

New Biotech Business Models From 1999

Advice of Counsel predicts the seven new business models that are likely to predominate in the months ahead, including "made to order" service deals; second-generation database companies; technology transfer from biotechs to big pharma; building a company to sell; holding onto a share of the upside of a late-stage product; skipping the high-risk phases of drug development; and diversifying the risk-reward tradeoff.
BioPharmaceutical Strategy

Genetic MicroSystems Inc.

Genetic MicroSystems is developing instrumentation that enables scientists to create DNA Chips and other biochips and to read them. The company's strategy is to develop equipment affordable to the individual researcher. (Update: Company has since been acquired by Affymetrix, in September 1999).
BioPharmaceutical Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Thermo Fisher Scientific Inc.
  • Senior Management
  • Jean Montagu, Pres. & CEO
    Mike Ryan, Dir., Manufacturing
    Stanley D Rose, PhD, VP, COO
    Peter Lewis, VP, Fin.
    Greg McGuinness, Dir., Sales
    Peter D Honkanen, VP, Engineering
    Linda Pettingell, VP, Human Resources
  • Contact Info
  • Genetic MicroSystems Inc.
    Phone: (781) 932-9333
    34 Commerce Way
    Woburn, MA 01801
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register